News
With certain drug shortages persisting across the U.S., pharmacy leaders are adopting more coordinated strategies to manage supply disruptions. These include expanding on-hand inventory for critical ...
Treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis are under review.
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced ...
Study harnesses a cell-type-specific, multi-target drug discovery strategy grounded in human data and real-world evidence.
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...
4h
The Brighterside of News on MSNTwo FDA-approved cancer drugs significantly reverse Alzheimer's disease
Alzheimer’s disease remains one of medicine’s toughest challenges, affecting millions and costing trillions of dollars ...
The Supreme Court’s recent unanimous decision on FDA’s drug-approval authority is utterly unremarkable.
17h
Discover Magazine on MSNTwo Cancer Drugs Show Surprising Promise in Treating Alzheimer's
With so few Alzheimer's drugs available, repurposing medications approved for other conditions could be the key to tackling ...
An analysis from the Congressional Budget Office warns that cuts to the National Institutes of Health and FDA drug reviews could significantly reduce the number of new medications reaching the U.S.
Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...
Participants in trials of BrainStorm Cell Therapeutics' NurOwn filed a Citizens’ Petition with the FDA earlier this month ...
The U.S. government is nixing a whole slew of "obsolete" U.S. food standards that Trump administration officials say also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results